BUND FINANCE › Stocks › ILMN
Illumina, Inc. (ILMN)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is -15.47% below its 50-day average.
- It is +16.61% above its 200-day average (long-term uptrend).
- It sits at 49% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$4.5B | US$4.6B | US$4.5B | US$4.4B | US$4.3B |
| Net income | US$762.0M | −US$4.4B | −US$1.2B | −US$1.2B | US$850.0M |
| EPS (diluted) | 5.05 | -28.05 | -7.35 | -7.69 | 5.45 |
| Gross margin | 69.7% | 64.8% | 60.9% | 65.4% | 66.1% |
| Operating margin | -2.7% | -91.2% | -23.7% | -19.1% | 18.6% |
| Net margin | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% |
| Free cash flow | US$337.0M | US$106.0M | US$283.0M | US$709.0M | US$931.0M |
| Total debt | US$2.5B | US$3.6B | US$2.3B | US$2.6B | US$2.6B |
| Cash | US$1.2B | US$2.0B | US$1.0B | US$1.1B | US$1.4B |
Compound annual growth: revenue -1.0% · net income 2.8% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 36.1x | 48.7x | 27.1x |
| EV / EBITDA | 23.6x | 31.5x | 16.5x |
| Operating margin | 22.4% | — | 3.6% |
| Net margin | 19.7% | — | -0.0% |
| Debt / equity | 1.17 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Illumina, Inc.
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and …
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice